A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.

Invest New Drugs 2013 Oct 17;31(5):1182-91. Epub 2013 Jul 17.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, 610 University Avenue, 5-125, M5G 2M9, Toronto, ON, Canada.

Background: To determine the recommended phase II dose (RP2D) and assess the safety, pharmacokinetics (PKs) and pharmacodynamics of RO4929097in combination with temsirolimus.

Methods: Escalating doses of RO4929097 and temsirolimus were administered at three dose levels. Patients received once daily oral RO4929097 on a 3 days on/4 days off schedule every week, and weekly intravenous temsirolimus. Blood samples were collected for PK analysis. Archival tissue specimens were collected for Notch pathway biomarker analysis and genotyping of frequent oncogenic mutations.

Results: Seventeen patients with refractory advanced solid tumors were enrolled in three dose levels (DLs): DL1 (RO4929097 10 mg; Temsirolimus 25 mg), DL2 (RO4929097 20 mg; Temsirolimus 25 mg), and DL3 (RO4929097 20 mg; Temsirolimus 37.5 mg). The most common toxicities related to the study drug combination included: fatigue (82 %; grade 3 6 %), mucositis, (71 %; grade 3 6 %), neutropenia (59 %; grade 3 12 %), anemia (59 %; grade 3 0 %), and hypertriglyceridemia (59 %; grade 3 0 %). Two dose-limiting toxicities, grade 3 rash and grade 3 mucositis, were observed in the same patient in the first dose level prompting dose expansion. Eleven patients (73 %) had stable disease as their best response. Co-administration of RO4929097 was associated with increased clearance and reduced exposure to temsirolimus, suggestive of drug-drug interaction via CYP3A4 induction. No correlation between the expression of Notch pathway biomarkers or genotype and time to progression was noted.

Conclusions: RO4929097 can be safely combined with temsirolimus in patients with advanced solid tumors. The RP2D was established at 20 mg of RO4929097 combined with 37.5 mg of temsirolimus.

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-013-0001-5
Publisher Site
http://dx.doi.org/10.1007/s10637-013-0001-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771370PMC
October 2013
43 Reads

Publication Analysis

Top Keywords

ro4929097 temsirolimus
16
advanced solid
12
solid tumors
12
temsirolimus
9
ro4929097
9
temsirolimus patients
8
grade mucositis
8
dose levels
8
patients advanced
8
notch pathway
8
three dose
8
grade
7
dose
5
patients
5
mucositis grade
4
fatigue grade
4
combination included
4
study drug
4
drug combination
4
grade neutropenia
4

References

(Supplied by CrossRef)

DC Allred et al.
Mod Pathol 1998

S Artavanis-Tsakonas et al.
Science 1999

BC Dickson et al.
Mod Pathol 2007

I Duran et al.
Eur J Cancer 2006

EA Eisenhauer et al.
Eur J Cancer 2009

DW Jenkins et al.
Mol Cancer Ther 2012

L Luistro et al.
Cancer Res 2009

T Palomero et al.
Nat Med 2007

E Raymond et al.
J Clin Oncol 2004

M Reedijk et al.
Cancer Res 2005

P Rizzo et al.
Oncogene 2008

Similar Publications